Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06612970
PHASE1
A Study to Evaluate Single-dose of HB0056 in Healthy Adult Participants
Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd.
View on ClinicalTrials.gov
Summary
The aim of this study is to investigate the safety and tolerability of HB0056 in healthy subjects following single-dose.
Official title: A Phase 1a, Randomized, Double-blind, Placebo-controlled, Single Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HB0056 in Adult Healthy Subjects.
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
46
Start Date
2024-11-18
Completion Date
2025-10-01
Last Updated
2025-09-08
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
HB0056
HB0056 Injection
DRUG
Placebo
Placebo
Locations (1)
New Zealand Clinical Research
Christchurch, New Zealand